Andrew K Cheng
Overview
Explore the profile of Andrew K Cheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
2464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee W, Cheng A
Antivir Ther
. 2022 May;
27(2):13596535211067600.
PMID: 35499175
Tenofovir alafenamide fumarate is a lipophilic prodrug of tenofovir which is preferentially metabolized in lymphatic tissue resulting in high concentrations of tenofovir (TFV) and its active diphosphate metabolite inside the...
2.
Gallant J, Daar E, Raffi F, Brinson C, Ruane P, DeJesus E, et al.
Lancet HIV
. 2016 Apr;
3(4):e158-65.
PMID: 27036991
Background: Emtricitabine with tenofovir disoproxil fumarate is a standard-of-care nucleoside reverse transcriptase inhibitor (NRTI) backbone. However, tenofovir disoproxil fumarate is associated with renal and bone toxic effects; the novel prodrug...
3.
Mills A, Arribas J, Andrade-Villanueva J, DiPerri G, van Lunzen J, Koenig E, et al.
Lancet Infect Dis
. 2015 Nov;
16(1):43-52.
PMID: 26538525
Background: Antiretroviral regimens containing tenofovir disoproxil fumarate have been associated with renal toxicity and reduced bone mineral density. Tenofovir alafenamide is a novel tenofovir prodrug that reduces tenofovir plasma concentrations...
4.
Sax P, Wohl D, Yin M, Post F, DeJesus E, Saag M, et al.
Lancet
. 2015 Apr;
385(9987):2606-15.
PMID: 25890673
Background: Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma...
5.
Saez-Llorens X, Castano E, Rathore M, Church J, Deville J, Gaur A, et al.
Pediatr Infect Dis J
. 2015 Mar;
34(4):376-82.
PMID: 25760565
Background: The safety and efficacy of tenofovir disoproxil fumarate (TDF) in HIV-1-infected children have not been evaluated in a randomized controlled trial. Methods: Subjects (2 to <16 years) on a...
6.
Post F, Winston J, Andrade-Villanueva J, Fisher M, Liu Y, Beraud C, et al.
J Acquir Immune Defic Syndr
. 2014 Dec;
68(3):310-3.
PMID: 25469527
In HIV-1-infected treatment-naive patients with mild-to-moderate renal impairment [creatinine clearance (CrCl): 50-89 mL/min], elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB, n = 33) achieved high rates of virologic success (78.8%; 95% confidence interval: 61.1%...
7.
Kulkarni R, Abram M, McColl D, Barnes T, Fordyce M, Szwarcberg J, et al.
HIV Clin Trials
. 2014 Oct;
15(5):218-30.
PMID: 25350960
Objective: To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-1-infected, treatment-naïve subjects through 144 weeks. Method: This was a randomized,...
8.
White K, Kulkarni R, McColl D, Rhee M, Szwarcberg J, Cheng A, et al.
Antivir Ther
. 2014 Oct;
20(3):317-27.
PMID: 25321623
Background: Here, the baseline and emergent resistance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) versus efavirenz (EFV)/FTC/TDF in HIV-1-infected antiretroviral-naive adults through 144 weeks from the randomized, ongoing, Phase III study GS-US-236-0102...
9.
Wohl D, Cohen C, Gallant J, Mills A, Sax P, DeJesus E, et al.
J Acquir Immune Defic Syndr
. 2013 Nov;
65(3):e118-20.
PMID: 24256630
No abstract available.
10.
Mills A, Cohen C, DeJesus E, Brinson C, Williams S, Yale K, et al.
HIV Clin Trials
. 2013 Oct;
14(5):216-23.
PMID: 24144898
Background: Due to ongoing neuropsychiatric adverse events in some efavirenz (EFV)-treated patients, a switch to an alternative non-nucleoside reverse transcriptase inhibitor may be considered. Rilpivirine (RPV) has been coformulated as...